(lp0
S"Peregrine Pharmaceuticals : What's Next? Insider Financial - Mar 14, 2017 Our regular readers will be more than aware by now that Peregrine Pharmaceuticals  is a company we keep on coming back to.Company Update : Peregrine Pharmaceuticals Announces Financial ... - Smarter AnalystPeregrine Pharmaceuticals'  CEO Steve King on Q3 2017 Results - Earnings ... - Seeking Alpha"
p1
aS"Peregrine Pharmaceuticals 's Run Validates Our Thesis Insider Financial - Feb 21, 2017 Our regular readers will know that Peregrine Pharmaceuticals  is one of the companies we have long highlighted as one that we see as being undervalued, and by proxy, due a revaluation.What Next For Peregrine Pharmaceuticals  After Proof of Concept? - StockNewsUnion28 institutional investors are raising stakes in Peregrine Pharmaceuticals ... - Post Analyst"
p2
aS"Today's Research Reports on Trending Biotech Tickers: Peregrine ... Yahoo Finance - Mar 9, 2017 Peregrine Pharmaceuticals' shares declined 1.86 percent to close at $0.68 a share on Wednesday. The stock traded between $0.65 and $0.69 on volume of 3.18 million shares traded."
p3
aS"Peregrine Pharmaceuticals  Upgraded to Buy by Zacks Investment Research Chaffey Breeze - 11 hours ago Peregrine Pharmaceuticals logo Zacks Investment Research upgraded shares of Peregrine Pharmaceuticals  from a hold rating to a buy rating in a report issued on Friday morning.Trader's Buzzers: Peregrine Pharmaceuticals, Inc.  - TopChronicleSell-side Consensus on Peregrine Pharmaceuticals, Inc.  Advanced ... - Davidson Register"
p4
aS'Peregrine Pharmaceuticals  Is One To Watch Ahead Of Earnings Insider Financial - Mar 6, 2017 Our more regular readers will know that Peregrine Pharmaceuticals  is one of the stocks we visit regularly. The company - as we have stated in the past, and an opinion that still stands - is one of the most mis-valued/misunderstood ...Peregrine Pharmaceuticals Inc.: Peregrine to Report Financial Results for ... - The Wall Street Transcript'
p5
aS'Ronin Capital Shows New 6.8% Stake in Peregrine Pharmaceuticals  - 13D StreetInsider.com - Mar 2, 2017 Stephen White is the indirect beneficial owner of all of the securities of Peregrine Pharmaceuticals, Inc. held of record or beneficially owned by SW Investment Management LLC by virtue of his having sole voting and dispositive power over such shares.Is Peregrine Pharmaceuticals, Inc.  Preparing For A Breakout Trade? - Post AnalystInvestor Research Report on Peregrine Pharmaceuticals, Inc.  - FactsReporter'
p6
aS"BRIEF-Peregrine Pharmaceuticals Q3 loss per share $0.04 Reuters - Mar 13, 2017 Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news&nbsp;..."
p7
aS"PEREGRINE PHARMACEUTICALS, INC.  Files An 8-K Other Events Market Exclusive - Mar 9, 2017 Peregrine Pharmaceuticals, Inc.  is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which&nbsp;...What's Happening To These Stocks?  Peregrine Pharmaceuticals, Inc. (PPHM ... - Post Analyst"
p8
aS'Average Brokerage Rating Of Peregrine Pharmaceuticals, Inc. , W&amp;T ... The USA Commerce - Mar 17, 2017 Peregrine Pharmaceuticals, Inc.  share price decreased in the last trading session with a previous 52-week high of $0.77.Peregrine Pharmaceuticals  Short Interest Update - Chaffey BreezeNoticeable Buzzer: Peregrine Pharmaceuticals Inc.  - Is stories'
p9
aS'Peregrine Pharmaceuticals Inc.  EPS Projection At $-0.005 RealistInvestor.com - 10 hours ago Peregrine Pharmaceuticals Inc.  is likely to account earnings of $-0.005 for prior quarter, which can come on 2017-07-13.'
p10
a.